Patents by Inventor Charles Z. Ding

Charles Z. Ding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTAL FORM OF EGFR INHIBITOR AND PREPARATION METHOD THEREOF
    Publication number: 20220194959
    Abstract: Disclosed are a crystal form of an EGFR inhibitor and a preparation method thereof. Further disclosed is an application of the crystal form in preparing a drug for treating non-small cell lung cancer, especially an application in preparing a drug for treating non-small cell lung cancer with brain metastases.
    Type: Application
    Filed: April 10, 2020
    Publication date: June 23, 2022
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Xile LIU, Lu ZHANG, Charles Z. DING, Shuhui CHEN, Lihong HU
  • SMAC mimetics used as IAP inhibitors and use thereof
    Patent number: 11358950
    Abstract: Disclosed are a class of SMAC mimetics used as IAP inhibitors, and in particular disclosed are compounds as shown in formula (I), isomers thereof, and pharmaceutically acceptable salts thereof. The IAP inhibitors are drugs for treating cancers, in particular breast cancer.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: June 14, 2022
    Assignee: CHIA TAI TIANGQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Yingchun Liu, Zhaobing Xu, Lihong Hu, Charles Z. Ding, Xingxun Zhu, Guoping Hu, Jian Li, Shuhui Chen
  • CRYSTALLIZATION OF SMAC MIMIC USED AS IAP INHIBITOR AND PREPARATION METHOD THEREOF
    Publication number: 20220177453
    Abstract: Provided are a crystallization of an SMAC mimic used as an IAP inhibitor and a preparation method thereof; also comprised is the use of said crystallization in the preparation of a drug for treating cancer benefiting from cIAP1 inhibition. The compound of formula (I) has high crystallization stability and low hygroscopicity, and has advantages in terms of physical properties, safety, and metabolic stability, and has high drug value.
    Type: Application
    Filed: May 9, 2020
    Publication date: June 9, 2022
    Inventors: Yingchun Liu, Zhaobing Xu, Lihong Hu, Charles Z. Ding, Xingxun Zhu, Shuhui Chen
  • COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR
    Publication number: 20220175917
    Abstract: The present invention relates to a combination of a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof which are used as an IAP inhibitor, and an immune checkpoint inhibitor; and use of the combination in the preparation of a cancer treatment drug.
    Type: Application
    Filed: March 6, 2020
    Publication date: June 9, 2022
    Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Yingchun LIU, Zhaobing XU, Shuhua HAN, Lihong HU, Charles Z. DING, Yuanfeng XIA, Haijun TONG, Lihua HE, Xin TIAN
  • INDOLO HEPTAMYL OXIME ANALOGUE AS PARP INHIBITOR
    Publication number: 20220144850
    Abstract: Disclosed is a type of indolo heptamyl oxime compounds as a PARP inhibitor. Specifically disclosed are a compound as represented by formula (II) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 3, 2020
    Publication date: May 12, 2022
    Inventors: Yanbin Hu, Gang Li, Fei Sun, Zhigang Chi, Jin Luo, Charles Z. Ding, Shuhui Chen
  • SALT OF EGFR INHIBITOR, CRYSTAL FORM, AND PREPARATION METHOD THEREFOR
    Publication number: 20220119431
    Abstract: Provided are a salt of an EGFR inhibitor, a crystal form thereof and a preparation method therefor, and an application of the salt and the crystal form in the preparation of a treatment for non-small cell lung cancer. The salt has a structure as shown in formula (II).
    Type: Application
    Filed: January 17, 2020
    Publication date: April 21, 2022
    Inventors: Lingyun WU, Xile LIU, Charles Z. DING, Shuhui CHEN, Lihong HU, Lele ZHAO, Wei PAN, Guoping HU, Jian LI, Ning ZHAO, Jun ZHAO
  • 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-ßR1 KINASE INHIBITOR
    Publication number: 20220098171
    Abstract: Disclosed are a group of 5-(4-pyridyloxy)pyrazole compounds serving as a TGF-?R1 kinase inhibitor, and applications of same in preparing a TGF-?R1 kinase inhibitor medicament. Specifically disclosed are the compounds as represented by formula (I), a pharmaceutically acceptable salt or an isomer thereof.
    Type: Application
    Filed: January 22, 2020
    Publication date: March 31, 2022
    Inventors: Xiangyu FU, Charles Z. DING, Lihong HU, Shuhui CHEN
  • APPLICATION OF MONOCYCLIC ß-LACTAM COMPOUND IN PHARMACY
    Publication number: 20220062244
    Abstract: An application of a compound represented by formula (I) and pharmaceutically acceptable salts thereof in preparation of a drug for treating pneumonia.
    Type: Application
    Filed: December 18, 2019
    Publication date: March 3, 2022
    Inventors: Xiawei WEI, Charles Z. DING, Jian LI, Shuhui CHEN, Yuquan WEI
  • Salt serving as AKT inhibitor and crystal thereof
    Patent number: 11261196
    Abstract: A salt serving as an Akt inhibitor and a crystal thereof, specifically related to a salt of the compound of formula (I) and a crystal thereof.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: March 1, 2022
    Assignee: HARBIN ZHENBAO PHARMACEUTICAL CO., LTD.
    Inventors: Gang Li, Lun Lu, Qingqing Lu, Lihong Hu, Charles Z. Ding
  • ESTROGEN RECEPTOR ANTAGONIST
    Publication number: 20220033376
    Abstract: Provided is an indole compound. In particular, disclosed are a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof and a use of the same as an estrogen receptor antagonist in preparing a drug for treating estrogen receptor-positive breast cancer.
    Type: Application
    Filed: December 17, 2019
    Publication date: February 3, 2022
    Inventors: Shuwen DUAN, Jianyu LU, Lihong HU, Charles Z. DING, Guoping HU, Jian LI, Shuhui CHEN
  • Crystal form and salt form of TGF-?RI inhibitor and preparation method therefor
    Patent number: 11236112
    Abstract: Disclosed in the present invention are a crystal form and salt form of a TGF-?R1 inhibitor and a preparation method therefor, and further disclosed is an application of the crystal form and the salt form in preparation of medicines for treating cancers.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: February 1, 2022
    Assignee: GENFLEET THERAPEUTICS (SHANGHAI) INC.
    Inventors: Lifang Wu, Huijun He, Jianyu Lu, Charles Z. Ding, Lihong Hu, Weidong Li, Shenyi Shi, Jian Li, Shuhui Chen
  • Salt Form of Estrogen Receptor Downregulator, Crystalline Form Thereof, and Preparation Method Therefor
    Publication number: 20220017463
    Abstract: Provided are a salt form of an estrogen receptor down-regulator, a crystalline form thereof, and a preparation method therefor.
    Type: Application
    Filed: October 17, 2019
    Publication date: January 20, 2022
    Inventors: Huijun HE, Shenyi SHI, Jianyu LU, Charles Z. DING, Lihong HU, Bin SHI, Wenqian YANG, Jiaqiang DONG, Tie-Lin WANG
  • Crystal Form of Hepatitis B Surface Antigen Inhibitor
    Publication number: 20220017536
    Abstract: The present invention discloses a crystal form of a hepatitis B surface antigen inhibitor and a preparation method therefor, and also comprises the use of the crystal form in preparing the hepatitis B surface antigen inhibitor.
    Type: Application
    Filed: November 22, 2019
    Publication date: January 20, 2022
    Inventors: Yanbin HU, Fei SUN, Shenyi SHI, Yanxiao SU, Charles Z DING
  • 3,9-DIAZASPIRO[5,5]UNDECANE COMPOUND AS FLT3 AND AXL INHIBITORS
    Publication number: 20210395252
    Abstract: Disclosed in the present invention is a novel compound as FLT3 and AXL inhibitors. Specifically, disclosed are a compound represented by formula (I) and a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: September 27, 2019
    Publication date: December 23, 2021
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Xiangyu FU, Charles Z. DING, Lihong HU, Jianyu LU, Wen JIANG, Jian LI, Shuhui CHEN
  • PYRIDONE-PYRIMIDINE DERIVATIVE ACTING AS KRASG12C MUTEIN INHIBITOR
    Publication number: 20210371411
    Abstract: Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 18, 2019
    Publication date: December 2, 2021
    Inventors: Yaxian CAI, Zhaobing XU, Hailong YANG, Shiqi HAN, Guoping HU, Lihong HU, Charles Z. DING, Jian LI, Shuhui CHEN
  • TLR8 AGONIST
    Publication number: 20210371414
    Abstract: A TLR8 (Toll-like receptor 8) agonist, a compound of the structure shown in formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 19, 2019
    Publication date: December 2, 2021
    Inventors: Zhe Cai, Fei Sun, Charles Z. Ding, Shuhui Chen
  • SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF
    Publication number: 20210371400
    Abstract: Disclosed are a class of SMAC mimetics used as IAP inhibitors, and in particular disclosed are compounds as shown in formula (I), isomers thereof, and pharmaceutically acceptable salts thereof. The IAP inhibitors are drugs for treating cancers, in particular breast cancer.
    Type: Application
    Filed: November 13, 2018
    Publication date: December 2, 2021
    Inventors: Yingchun Liu, Zhaobing Xu, Lihong Hu, Charles Z. Ding, Xingxun Zhu, Guoping Hu, Jian Li, Shuhui Chen
  • URACIL COMPOUND AS C-MET/AXL INHIBITOR
    Publication number: 20210371395
    Abstract: Provided are a uracil compound represented by Formula (IV) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition of the same. Also provided is a use thereof as a c-MET/AXL inhibitor in preparing a c-MET/AXL-inhibiting drug or a drug for treating a tumor.
    Type: Application
    Filed: November 23, 2018
    Publication date: December 2, 2021
    Applicant: MEDSHINE DISCOVERY, INC.
    Inventors: Jinping LI, Xiongbin XU, Gang LI, Lihong HU, Charles Z. DING, Yaling ZHOU, Guoping HU, Jian LI, Shuhui CHEN
  • Crystal form of ?-lactamase inhibitor and preparation method therefor
    Patent number: 11180501
    Abstract: Disclosed in the present disclosure are a crystal form of a ?-lactamase inhibitor and a preparation method therefor, as well as an application of the crystal form in preparing a ?-lactamase inhibitor drug.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: November 23, 2021
    Assignee: QILU PHARMACEUTICAL CO., LTD.
    Inventors: Cheng Li, Zhigang Huang, Charles Z. Ding, Weidong Li
  • TLR8 AGONIST
    Publication number: 20210340141
    Abstract: The present invention relates to a structurally novel TLR8 (Toll-like receptor 8) agonist and, in particular, to a compound thereof of formula (I), a pharmaceutically acceptable salt and an isomer thereof.
    Type: Application
    Filed: October 18, 2019
    Publication date: November 4, 2021
    Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Fei SUN, Zhe CAI, Charles Z. DING, Shuhui CHEN